EWTX Latest Press Releases

-- November 9, 2026 --

/C O R R E C T I O N - Edgewise Therapeutics/ PRNewswire 11:42 AM

Edgewise Therapeutics to Participate in Upcoming Investor Conferences PRNewswire 8:00 AM

-- November 5, 2026 --

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring PRNewswire 8:00 AM

-- November 4, 2026 --

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results PRNewswire 4:01 PM

-- November 2, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:00 AM

-- October 8, 2026 --

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 PRNewswire 8:01 AM

-- October 1, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:01 AM

-- September 22, 2026 --

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 PRNewswire 7:00 AM

-- September 2, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:01 AM

-- August 24, 2026 --

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 PRNewswire 8:01 AM

-- August 6, 2026 --

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results PRNewswire 8:00 AM

-- July 13, 2026 --

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline PRNewswire 8:30 AM

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business PRNewswire 8:30 AM

-- July 1, 2026 --

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PRNewswire 8:00 AM

-- June 16, 2026 --

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum Globe Newswire 10:18 AM

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) PRNewswire 7:00 AM

Market Data Delayed 15 Minutes